Trial Profile

A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects With Schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ulotaront (Primary) ; Quetiapine
Indications Schizophrenia
Focus Adverse reactions; Registrational
Sponsors Otsuka Pharmaceutical Development & Commercialization; Sumitomo Pharma America

Most Recent Events

15 Feb 2023 Status changed from active, no longer recruiting to completed.
16 Feb 2022 Planned End Date changed from 4 Mar 2022 to 10 Jan 2023.
16 Feb 2022 Planned primary completion date changed from 4 Mar 2022 to 10 Jan 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com